Funder
Orion Corporation Orion Pharma
Bayer AG
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference35 articles.
1. Fizazi K, Smith MR, Tombal B. Clinical development of darolutamide: a novel androgen receptor antagonist for the treatment of prostate cancer. Clin Genitourin Cancer. 2018;16(5):332–40.
https://doi.org/10.1016/j.clgc.2018.07.017
.
2. US Food and Drug Administration. FDA approves darolutamide for non-metastatic castration-resistant prostate cancer. 2019.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer
. Accessed 31 July 2019.
3. Bayer HealthCare Pharmaceuticals Inc. Nubeqa (darolutamide) US prescribing information. 2019.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf
. Accessed 31 July 2019.
4. Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15(9):975–85.
https://doi.org/10.1016/s1470-2045(14)70240-2
.
5. Massard C, Penttinen HM, Vjaters E, Bono P, Lietuvietis V, Tammela TL, et al. Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol. 2016;69(5):834–40.
https://doi.org/10.1016/j.eururo.2015.09.046
.
Cited by
71 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献